Quick Takeaways
- James E. Flynn filed SCHEDULE 13G/A for Cullinan Therapeutics, Inc. Common Stock (CGEM).
- Disclosed ownership: 5%.
- Date of event: 30 Sep 2025.
James E. Flynn - 30 Sep 2025 SCHEDULE 13G/A Report for Cullinan Therapeutics, Inc. Common Stock (CGEM)
- Filing Manager
- James E. Flynn
- Reporting Manager
- Deerfield Mgmt, L.P.
- Symbol
- CGEM
- Shares outstanding
- 59,131,576 shares
- Disclosed Ownership
- 2,927,013 shares
- Ownership
- 5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Nov 2025, 16:28:46 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"James E. Flynn disclosed 5% ownership in Cullinan Therapeutics, Inc. Common Stock (CGEM) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Nov 2025, 16:28.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deerfield Mgmt, L.P. | 5% | 2,927,013 | 0 | 2,927,013 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact | |
| Deerfield Management Company, L.P. | 5% | 2,927,013 | 0 | 2,927,013 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact | |
| Deerfield Partners, L.P. | 5% | 2,927,013 | 0 | 2,927,013 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact | |
| James E. Flynn | 5% | 2,927,013 | 0 | 2,927,013 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact |